Sarepta Therapeutics Inc Stock Price, News & Analysis

Sarepta Therapeutics reported strong financial results for Q4 and full-year 2022, with total revenues of $258.4 million for the quarter and $933.0 million for the year. Net product revenues increased 32% year-over-year in Q4 and 38% for the full year. The company reported a net loss of $109.2 million for Q4 and $703.5 million for the year. The FDA accepted the Biologics License Application for SRP-9001, granting it Priority Review, with an expected decision on May 29, 2023. Sarepta's ongoing commitment to patient care and its pipeline growth, including new gene therapy candidates, positions it strongly in the genetic medicine market.

Sarepta Therapeutics (NASDAQ:SRPT) has launched its Route 79 Duchenne Scholarship Program for the 2023-2024 academic year, accepting applications until May 5, 2023. Scholarships of up to $5,000 will be awarded to 20 individuals diagnosed with Duchenne muscular dystrophy and five siblings. This initiative, now in its sixth year, aims to support educational pursuits for these individuals. Interested applicants must be enrolled in an accredited U.S. college or vocational school. Since 2018, 84 scholarships have been awarded, showcasing Sarepta's commitment to the Duchenne community.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will release its fourth quarter and full year 2022 financial results after market close on February 28, 2023. A conference call will follow at 4:30 p.m. E.T. to discuss the financials and provide a corporate update. Investors can access the event via a live webcast on Sarepta's investor relations webpage, with a replay available for one year post-event. The company is a leader in precision genetic medicine, specifically focusing on rare diseases like Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), supported by over 40 active development programs.

Sarepta Therapeutics (NASDAQ:SRPT) has announced the dosing of the first patient in its Phase 1 study, VOYAGENE (Study SRP-9003-102), for SRP-9003 (bidridistrogene xeboparvovec), aimed at treating limb-girdle muscular dystrophy Type 2E/R4 (LGMD2E). This U.S.-only trial will enroll ambulant patients aged 18 and older, and non-ambulant patients aged 4-50. Previous studies showed positive data for SRP-9003 in younger patients. The ongoing development emphasizes urgency in advancing new treatments, as existing options only manage symptoms and do not address the disease's progression.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced on January 31, 2023, the granting of equity awards to 40 newly hired employees. This decision was made by the Compensation Committee under the 2014 Employment Commencement Incentive Plan. A total of 41,125 stock options and 22,100 restricted stock units (RSUs) were awarded, with options priced at $124.97 per share, aligning with the closing stock price on the grant date. Vesting for options occurs monthly over four years, while RSUs vest annually. Sarepta focuses on developing precision genetic medicine for rare diseases, including Duchenne muscular dystrophy.

Sarepta Therapeutics (NASDAQ:SRPT) anticipates exceeding its 2022 net product revenue guidance. Preliminary fourth quarter 2022 net product revenues are expected to reach $235.5 million, a 32% increase compared to the same quarter in 2021. For the full year, revenue is projected at $843.3 million, a 38% increase year-over-year, surpassing the previous guidance of $825-840 million. The company reported a year-end cash balance of approximately $2.0 billion. The final financial results will be disclosed in late February 2023.

Catalent and Sarepta Therapeutics have entered into a commercial supply agreement for Catalent to manufacture Sarepta’s gene therapy candidate, delandistrogene moxeparvovec (SRP-9001), aimed at treating Duchenne muscular dystrophy (DMD). This agreement names Catalent as Sarepta's primary manufacturing partner for SRP-9001 and supports additional candidates in Sarepta’s pipeline for limb-girdle muscular dystrophy (LGMD). Catalent boasts advanced manufacturing capabilities with 10 cGMP gene therapy suites, with 8 more under construction.

Sarepta Therapeutics (NASDAQ:SRPT) has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 1:30 p.m. E.T. in San Francisco, California. A Q&A session will follow at 1:50 p.m. E.T. The presentation will be available via live webcast on Sarepta's investor relations website and archived for 90 days thereafter. Sarepta focuses on precision genetic medicine for rare diseases, with over 40 programs in development, particularly in Duchenne muscular dystrophy and limb-girdle muscular dystrophies. For more details, visit their website.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced the granting of equity awards to 42 newly hired employees as of November 30, 2022. The awards, approved by the Compensation Committee under the 2014 Employment Commencement Incentive Plan, include options to purchase 55,000 shares and 28,500 restricted stock units (RSUs). The options have an exercise price of $122.81 per share, equal to the stock's closing price on the grant date. Both the options and RSUs will vest over four years, contingent upon continued employment.